- In October 2022, Grifols launched a state-of-the-art albumin purification and filling operation in Dublin, Ireland, significantly enhancing its global production and supply capabilities. This facility is part of Grifols’ strategic initiative to expand its footprint in the albumin market, ensuring high-quality production standards and increased efficiency in fulfilling global demand for this critical plasma-derived product
- In September 2022, The Ministry of Health, Labour, and Welfare of Japan granted CSL Behring K.K. the manufacturing and marketing approval for Berinert S.C. Injection 2000. This product is a lyophilized human C1-esterase inhibitor concentrate designed for subcutaneous injection, specifically aimed at preventing acute hereditary angioedema (HAE) attacks. The approval marks a significant advancement in treatment options available for patients suffering from HAE
- In April 2022, Takeda Pharmaceutical Company Limited completed its acquisition of Shire Plc, a strategic move that enhances Takeda's portfolio in the plasma market. This acquisition allows Takeda to expand its range of products significantly and solidifies its position within the plasma fractionation industry, aiming to improve patient outcomes through a broader offering of therapies derived from human plasma
